CTD Holdings Finalizes Cooperative Agreement for Alzheimer’s Disease Research Program

CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today that the company has finalized a cooperative research agreement with Kerwin Research Center, LLC to explore the use of cyclodextrins in the treatment of Alzheimer’s disease. “With this cooperative research program, we are proud to continue to innovate by exploring the use of Trappsol® Cyclo™ in the treatment of Alzheimer’s disease.”Cholesterol has been linked to the formation of amyloid beta plaques, one of the hallmarks of Alzheimer’s disease.”I am excited for the opportunity to work with CTD on this potential new therapeutic approach in Alzheimer’s disease.
Read the Full Story at markets.businessinsider.com